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Background: Triggering receptor expressed on myeloid cells (TREM)-1 is a recently
described molecule that plays an important role in myeloid cell-activated inflammatory
responses. The aim of this study was to investigate the expression of TREM-1 in pleural
effusions of various causes.
Methods: For this cross-sectional, observational study conducted between February and
August 2005 in Taiwan, 74 patients with pleural effusions of varying etiology were
investigated. Soluble TREM-1 (sTREM-1) was measured in pleural fluid samples, and cells in
the fluid were assessed for surface expression of TREM-1.
Results: Concentrations of sTREM-1 were significantly higher in infectious and neoplastic
pleural effusions (189.1736.7 and 69.9722.8 ng/ml, mean7SEM) than in transudates
(10.175.3 ng/ml; Po0.001). Among infectious effusions, the sTREM-1 levels were
significantly higher in parapneumonic than in tuberculous effusions (301.8749.8 vs.
38.9717.3 ng/ml; Po0.001). TREM-1 was expressed on a portion of the myeloid (CD11b
positive) cells in each type of effusion, without significant differences among them
(transudative, 34.7%; neoplastic, 36.0%; parapneumonic, 27.7%; tuberculous, 21.2%;
P ¼ 0:861). Non-myeloid cells expressed very little TREM-1 (transudative, 6.3%; neoplas-
tic, 0.5%; parapneumonic, 1.0%; tuberculous, 0.7%; P ¼ 0:192).Elsevier Ltd. All rights reserved.
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C.-L. Liu et al.904Conclusions: sTREM-1 expression in pleural fluids is highest in parapneumonic and
neoplastic effusions but low in transudates. In infectious effusions, a high concentration
of sTREM-1 may exclude tuberculous pleurisy.
& 2006 Elsevier Ltd. All rights reserved.Introduction
The human triggering receptor expressed on myeloid cells
(TREM)-1 is a 30-kDa glycoprotein of the immunoglobulin
superfamily.1,2 In vitro and in vivo studies have shown that
TREM-1 expression is strongly up-regulated by extracellular
bacteria, particularly the cell wall component, and by fungi
although not by mycobacteria.2,3 In contrast, TREM-1 is
poorly expressed in noninfectious inflammatory diseases
such as psoriasis, ulcerative colitis and vasculitis, and in
granulomatous disorders such as tuberculosis or foreign body
granulomas.2,3 A soluble form of TREM-1 (sTREM-1) is
released from activated phagocytes and can be found in
body fluids. Recently, the levels of sTREM-1 in bronchoal-
veolar lavage (BAL) fluid have been shown to be a strong
independent predictor of ventilator-associated pneumo-
nia.4–6 Plasma concentrations of sTREM-1 correlate with
the clinical course of sepsis and thus may help identify
patients with infection.7–9
The pleura are dynamic, metabolically active membranes
responsible both for maintaining homeostasis and respond-
ing to insults resulting in inflammation.10,11 Acute inflam-
matory processes are associated with the development of an
inflammatory cell-rich pleural effusion, as well as produc-
tion of cytokines and chemokines.12 Such effusions fulfill the
criteria for exudates, whereas non-inflammatory processes
usually result in a transudative pleural effusion. As far as we
are aware, the expression of sTREM-1 in of pleural effusions
has not previously been investigated.
We designed this study to measure sTREM-1 in pleural
fluids of varying etiologies and to investigate the role of
myeloid cells in sTREM-1 expression.
Methods
Patients
Patients admitted to our hospital from January to August
2005 and who had pleural effusions were eligible for the
study. The study was approved by our institutional review
board, and all patients involved gave informed consent.
Fifty to 200ml of pleural fluid were collected from each
individual by echo-guided thoracentesis. Patients were
excluded if they had already received anti-inflammatory or
steroid therapy.
Pleural fluid evaluation
The effusions were sent for red and white blood cell (WBC)
counts, including absolute neutrophil and lymphocytecounts, and biochemistry tests, including pH, glucose,
protein, and lactate dehydrogenase (LDH). Most effusions
were also examined with Gram and acid-fast stains and
cultures for bacteria and mycobacteria. In some cases,
cytology studies were also done.
The pleural effusions were classified as follows: neoplas-
tic, including malignant (with either a cytologic or histologic
diagnosis of neoplasm within the pleural space) and
paramalignant (when a histologic diagnosis of malignant
tumor in another organ was established, the effusion itself
did not meet the malignant criteria, and no other cause of
pleural effusion was found); infectious, including tubercu-
lous (if pleural fluid or tissue cultures were positive for
Mycobacterium tuberculosis or if the remaining clinical
evidence was consistent with pleural tuberculosis) and
parapneumonic (if the patient had cough, fever, and a
radiographic pulmonary infiltrate that disappeared with
antibiotic treatment or an empyema, defined as pus in the
pleural space); or transudative (if the classic biochemical
criteria were met). If a definite etiology could not be
determined or there were several potential causes of
pleural effusion that could not be distinguished from one
another, the effusion was deemed to be of undetermined
cause. Patients were excluded from further analysis if the
effusion was of undetermined cause or was too complicated.
Measurement of sTREM-1 and flow cytometry
Pleural effusion specimens were collected without prior
fixation and a portion of the specimen was centrifuged,
after which 100 ml of the supernatant was dotted on a
nitrocellulose membrane, dried, and overcoated with
phosphate-buffered saline solution supplemented with 3%
bovine serum albumin. The nitrocellulose sheet was then
incubated for 60min in the presence of monoclonal anti-
TREM-1 antibody. After thorough rinsing, the sheet was
further incubated for 60min with diluted (1:1000) goat anti-
mouse immunoglobulin (Dako, Glostrup, Denmark), washed
in phosphate-buffered saline solution supplemented with
20% dimethylsulfoxide, and incubated for 30min with
diluted (1:1000) horseradish peroxidase-conjugated strep-
tavidin (Bio-Rad, Cergy, France). The enzyme substrate
chromogen Opti-4CN (Bio-Rad) was then added, resulting in
color development in proportion to the amount of soluble
TREM-1 bound to the membrane. Each sheet also contained
calibration samples of a known concentration of soluble
TREM-1 (0–5000 ng/ml). Colorimetric determination was
achieved by using a reflectance scanner and Quantity One
quantitation software (Bio-Rad). The concentration of
sTREM-1 was determined in each sample by plotting the
optical density of the sample against the standard curve. All
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were expressed as mean concentration in ng/ml of pleural
fluid.
Fresh pleural fluid samples (i.e., obtained within 6 h of
thoracentesis) were available for flow cytometry in 16 cases.
A portion of each sample was centrifuged at 1500 rpm for
5min, the supernatant was discarded, and the cell pellet
was washed with FACS washing buffer (1% FCS and 0.1% NaN3
in PBS). Cell surface staining was performed using the
following antibodies: CD3 (UCHT1, BD), CD14 (M5E2, BD),
CD19 (HIB19, BD), CD206 (19.2, BD) CD177 (MEM-166, BD),
NKp46 (9E2/NKp46, BD), with use of isotype controls
(immunoglobulin G1 and G2a, BD). This was followed by
treatment with the appropriate phycoerythrin (PE)- or
fluorescein isothiocyanate (FITC)-conjugated rat anti-mouse
secondary antibodies (A85-1, BD). The cells were analyzed
on a FACSCalobur (BD Pharmingen) using CellQuest 3.1
software. Expression levels were measured as mean channel
fluorescence values compared to the isotype control.
Myeloid cells in the effusions were also assessed for
expression of TREM-1. Cells were labeled with CD11b-FITC
antibody against TREM-1-PE-conjugated antibodies. Quad-
rant setting was performed according to the reactivities of
isotype-matched controls.Statistical analysis
All data are expressed as mean7SEM. Univariate analysis was
conducted using the Pearson chi-square test for categorical
variables and the Mann–Whitney U test for continuous
variables. The Spearman correlation test was used to look
for associations between the variables. The results were
considered statistically significant if P waso0.05. TheTable 1 Demographic and laboratory characteristics in 74 pati
Variable Transudative effusions
(n ¼ 19)
Ne
(n
Clinical and laboratory studies
Male/female, n 13/6 12
Mean age, years 69.874.3 66
Blood WBC count, 109 cells/l 64287408 82
Serum CRP, mg/dl 1.6470.35 4.
Effusion WBC count, 109 cells/l 4387109 89
L 303785 49
N 51724 69
Other 84726 33
Effusion glucose, mg/dl 183.6719.8 15
Effusion protein, g/dl 1.7170.21 3.
Effusion LDH, m/l 88.179.2 38
Soluble TREM-1 in pleural effusions
Effusion sTREM, ng/ml 10.175.3 69
Effusion sTREM-1/protein 5.672.8 20
Data are presented as mean7SEM unless otherwise indicated. CRP
significant; sTREM-1 ¼ soluble form of triggering receptor expressed
Po 0.01 compared to transudative group.
P o 0.01 compared to neoplastic group.
yPo 0.05 was considered significant.differences between groups were tabulated and analyzed
using SPSS software (version 10.0; Chicago, IL).Results
Characteristics of the study population
A total of 87 patients admitted with pleural effusion were
enrolled during the study period. Of these, 13 (15%) were
excluded because the cause of the effusion was undeter-
mined, leaving 74 for study (Table 1, Fig. 1). Of 19 patients
with transudative effusions, seven had chronic renal failure,
six congestive heart failure, four liver cirrhosis, and two
nephrotic syndrome.
Of the 15 patients with tuberculous effusions, 13 had
pulmonary tuberculosis and two extra-pulmonary (brain
abscess and meningitis) tuberculosis. None had a positive
acid-fast reaction in the pleural fluid, and only one had a
positive tuberculosis culture. Polymerase chain reaction for
tuberculosis was done on four effusions, with only one
positive result. None of the patients had a pleural biopsy.Clinical and laboratory studies
Patients with infectious pleural effusions had significantly
higher peripheral blood WBC counts and serum CRP values
than did those with neoplastic effusions. The latter, in turn,
had significantly higher peripheral WBC counts and
CRP levels than did patients with transudative effusions
(Table 1).ents with pleural effusions.
oplastic effusions
¼ 20)
Infectious effusions
(n ¼ 35)
P value
/8 20/15 NS
.972.8 72.572.6 NS
027385 113137762, o 0.001y
3570.65 11.9471.54, o 0.001y
87193 9777176 0.095
07119 444797 NS
720 4537119 0.004y
97125 80722 0.009y
8.4720.5 149.1712.3 NS
6770.15 3.4670.17 o 0.001y
1.9776.6 402.6773.5 0.006y
.9722.8 189.1736.7 o 0.001y
.177.0 62.4714.9 0.005y
¼ C-reactive protein; LDH ¼ lactate dehydrogenase; NS ¼ not
on myeloid cells-1; WBC ¼ white blood cell.
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Pleural Effusions 
n = 74
Parapneumonic 
n = 20 
Including
Pseudomonas (3),
Streptococcus (1), 
Haemophilus
influenzae (1), Serratia 
(1), Cytomegalovirus
(1), unknow netiology
(13)
Malignant 
n = 14 
Including lung
adenocarcinoma (8), 
breast (2), small cell 
lung (1), esophageal 
(1), tonsillar (1), and 
tongue (1) cancer.  
Tuberculous 
n = 15 
Including pulmonary
(13) and extra-
pulmonary (2)
tuberculosis
Paramalignant 
n = 6 
Including hepatoma
(2), breast (1),
metastatic 
schwannoma (1), 
malignant thymoma 
(1), metastatic 
adenocarcinoma (1)
Neoplastic 
n = 20 
Infectious 
n = 35 
Non-transudative 
n = 55 
Transudative 
n = 19 
Figure 1 Flow chart of the diagnosis of the pleural effusions.
C.-L. Liu et al.906Cellular profiles and biochemistry examinations of
pleural fluids
The WBC counts did not differ statistically among transuda-
tive, neoplastic, and infectious exudates. However, not
surprisingly, there were significantly more neutrophils in the
infectious exudates than the other two groups, while
neoplastic effusions had significantly more cells not classi-
fied as either lymphocytes or neutrophils. Both protein and
LDH concentrations were significantly higher in infectious
and neoplastic effusions than in transudates (Table 1).Soluble TREM-1 in pleural effusions
The levels of sTREM-1 were significantly higher in the non-
transudates compared with the transudates (145.8725.8 vs.
10.175.3 ng/ml; Po0.001). Among the non-transudates,
sTREM-1 appeared to be higher in the infectious than in the
neoplastic effusions (189.1.6736.7 vs. 69.9722.8 ng/ml),
but this difference was not statistically significant (Table 1).
Among the neoplastic effusions, the sTREM-1 levels of
malignant and para-malignant effusions did not differ
significantly (Table 2). However, among the infectious
effusions, parapneumonic effusions had significantly higher
sTREM-1 levels than did tuberculous effusions (301.8749.8vs. 38.9717.3 ng/ml, Po0.001) (Table 3). Parapneumonic
effusions also had significantly higher levels of sTREM-1 than
did malignant effusions (P ¼ 0:001), and the latter had
significantly higher levels than did transudates (P ¼ 0:026)
(Fig. 2).
Myeloid cells and TREM-1 expression in pleural
effusions
Flow cytometry of 16 pleural fluid specimens showed that
TREM-1 was expressed almost exclusively on myeloid (CD11b
positive) cells. The percentage of myeloid cells with TREM-1
expression did not differ significantly among various types of
effusions (transudative, 34.7%; neoplastic, 36.0%; parapneu-
monic, 27.7%; tuberculous, 21.2%; P ¼ 0.861). Only very low
percentages of non-myeloid cells expressed TREM-1 (trans-
udative, 6.3%; neoplastic, 0.5%; parapneumonic, 1.0%;
tuberculous, 0.7%; P ¼ 0:192) (Table 4).
Discussion
In this cross-sectional study, we have described the levels of
sTREM-1 and TREM-1 expression on CD11b myeloid cells in
pleural effusions of differing etiologies. sTREM-1 was
present in higher concentrations in inflammatory (neoplastic
ARTICLE IN PRESS
Table 2 Hematologic and biochemical analysis of blood and pleural fluids in neoplastic effusions.
Neoplastic P value
Malignant (n ¼ 14) Paramalignant (n ¼ 6)
Clinical and laboratory studies
Age, y 66.173.5 68.875.2 NS
Male/female 7/7 5/1 NS
Blood WBC count, 109 cells/l 83797439 77887811 NS
Serum CRP, mg/dl 4.6370.82 3.7471.14 NS
Effusion WBC count, 109 cells/l 8957237 9057358 NS
L 3807107 7477300 NS
N 87727 29714 NS
Other 4307172 129781 NS
Effusion glucose, mg/dl 149.8724.6 178.4739.1 NS
Effusion protein, g/dl 3.6070.13 3.8270.43 NS
Effusion LDH, m/l 446.6799.4 230.8787.9 NS
Soluble TREM-1 in pleural effusions
Effusion sTREM, ng/ml 84.1731.1 37.0720.0 0.358
Effusion sTREM-1/protein 24.379.1 10.576.4 0.361
Data are presented as mean7SEM unless otherwise indicated. CRP ¼ C-reactive protein; LDH ¼ lactate dehydrogenase; NS ¼ not
significant; sTREM-1 ¼ soluble form of triggering receptor expressed on myeloid cells-1; WBC ¼ white blood cell.
Po0.05 was considered significant.
Table 3 Hematologic and biochemical analysis of blood and pleural fluids in infectious effusions.
Infectious P value
Parapneumonic (n ¼ 20) Tuberculous (n ¼ 15)
Clinical and laboratory studies
Age, y 70.673.5 75.074.1 NS
Male/female 10/10 10/5 NS
Blood WBC count, 109 cells/l 1303371053 90197793 0.007
Serum CRP, mg/dl 12.6271.99 10.7072.51 NS
Effusion WBC count, 109 cells/l 11407274 7597181 NS
L 4077143 4937127 NS
N 6317180 2167121 0.065
Other 103732 50728 NS
Effusion glucose, mg/dl 165.0719.1 128.0711.9 NS
Effusion protein, g/dl 3.5270.25 3.3870.25 NS
Effusion LDH, m/l 437.87105.1 355.87101.5 NS
Soluble TREM-1 in pleural effusions
Effusion sTREM, ng/ml 301.8749.8 38.9717.3 o0.001
Effusion sTREM-1/Protein 101.6722.4 10.074.5 0.001
Data are presented as mean7SEM unless otherwise indicated. CRP ¼ C-reactive protein; LDH ¼ lactate dehydrogenase; NS ¼ not
significant; sTREM-1 ¼ soluble form of triggering receptor expressed on myeloid cells-1; WBC ¼ white blood cell.
Po0.05 was considered significant.
Triggering receptor expressed on myeloid cells-1 in pleural effusions 907or infectious) effusions than in transudates, but the levels in
tuberculous effusions were not as high as in parapneumonic
effusions. This raises the possibility that measuring sTREM-1
might be a way of distinguishing effusions secondary to
tuberculosis from those caused by other inflammatory
processes. TREM-1 expression on myeloid cells, ranging
from one third to one half of such cells, did notdiffer enough among the different entities to be clinically
useful.
Innate immunity involves many facets of host defense
against pathogenic microbes, including the recognition of
pathogen-associated molecular patterns,12 providing both
initial protection against microorganisms and also stimulat-
ing the adaptive immune response.13 TREM-1 is a newly
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C.-L. Liu et al.908identified cell-surface receptor found on neutrophils, a
subset of monocytes, and on lung alveolar macrophages.
This particular cellular and tissue distribution pattern
suggests a role for TREM-1 in the inflammatory response to
infection. In the presence of microbial compounds, cell-
surface TREM-1 expression is upregulated,14 and sTREM may
be a biomarker of infection.15 Our study adds to the body of
information available about this compound by describing its
presence in pleural effusions in humans.
The Light criteria have proved a useful addition to clinical
judgment for classifying pleural effusions in transudates and
exudates,16 and they are particularly sensitive for exudative
effusions.17,18 However, the Light criteria misclassify 15% toTable 4 CD11b myeloid cells with TREM-1 expression (%).
Transudative (n ¼ 3) Neoplastic (n ¼ 3)
TREM+/CD11b- 6.3 0.5
(0.2–16.5) (0.0–0.9)
TREM+/CD11b+ 34.7 36.0
(13.6–62.8) (24.7–48.5)
TREM-/CD11b- 49.4 38.4
(31.3–77.2) (24.6–52.5)
TREM-/CD11b+ 9.7 25.3
(3.7–16.2) (12.1–51.3)
Data presented as median (range).
0
100
200
300
400
500
600
700
800
Tr M PaM PaP TB
p = 0.026 p = 0.001
p < 0.001
p < 0.001
Figure 2 sTREM-1 in the pleural effusion of patients with
transudative (Tr) [n ¼ 19; ], malignant (M) [n ¼ 14; m],
paramalignant (PaM) [n ¼ 6; n], parapneumonic (PaP)
[n ¼ 20; ~] and tuberculous pleural effusion (TB) [n ¼ 15;
}]. The levels of sTREM-1 are expressed in ng/ml. Each symbol
represents one individual. Horizontal bars represent mean
values.30% of transudates as exudates.18 Furthermore, determining
the etiology of an effusion when multiple possible causes
exist remains problematic. For example, in our series, there
were two patients with effusions who had evidence of
pneumonia on chest X-ray with, but they also had underlying
congestive heart failure and chronic renal insufficiency. Both
had had leukocytosis and an elevated CRP, but, by Light
criteria, their pleural effusions were transudates. However,
the elevated sTREM-1 levels (561 ng/ml and 563 ng/ml)
suggested that their effusions were in fact parapneumonic.
In Light’s classical description of the criteria, 33 of 150
patients (22%) were excluded because clinical criteria alone
were insufficient to determine the cause of the effusions.16
Similarly, we could not classify the effusions in 13 of 87 (15%)
patients initially considered for enrollment in our study.
It is likely, therefore, that no single test or group of tests
will distinguish transudates in marginal cases or where the
clinical circumstances are unclear. However, continued
development of new biochemical or immunologic tools
may eventually provide valuable clinical help.17,18 The
results of our study suggest that levels of sTREM-1 may help
differentiate between parapneumonic and tuberculous
effusions. Pleural effusions in tuberculosis are thought to
result from a delayed hypersensitivity reaction in response
to the presence of mycobacterial antigens in the pleural
space.19–21 They usually result in predominantly lymphocytic
exudates.22 However, cultures for mycobacteria are positive
in only 20–30% of pleural fluid samples eventually deter-
mined to be tuberculous in nature. The sensitivity of
polymerase chain reaction in active disease is reportedly
78%,23 but even this improvement still leaves 20% of
tuberculous pleural effusions defying a definitive diagnosis.
Other biochemical markers such as adenosine deaminase
(ADA), interferon-g, and lysozyme are of some help.24–26
However, given the nonspecific presentation of tuberculous
pleuritis, the diagnosis is often unsuspected during initial
investigation. Our study suggests that sTREM may help
exclude the diagnosis of tuberculosis, especially in areas
endemic for the disease.
A limitation of this study is the relatively small number of
patients. Because we divided them into different categories
based on the etiology of the effusion, the number in any
particular diagnostic category was low, thus increasing the
chance of a type II error. Measuring sTREM levels in pleural
effusions from a larger sample may demonstrate a greater
ability to distinguish among various causes of pleural
effusions. Another limitation was the small number ofParapneumonic (n ¼ 6) Tuberculous (n ¼ 4) P value
1.0 0.7 0.192
(0.3–2.3) (0.1–1.0)
27.7 21.2 0.861
(9.5–76.8) (1.5–69.9)
51.0 67.2 0.517
(1.7–69.7) (21.1–86.3)
20.3 10.9 0.209
(11.2–31.9) (9.0–12.5)
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cytometry. We assumed that that cells positive by flow
cytometry for both CD11b and TREM-1 were indeed myeloid
cells expressing TREM-1, but the percentage of such cells did
not differ significantly among the various types of effusions.
Given the small numbers involved, firm statistical inferences
cannot be drawn. However, we believe that overall our
results provide enough scientific evidence to allow these
questions to be addressed in further studies.
In conclusion, we have demonstrated that sTREM-1
appears to distinguish well between inflammatory (para-
pneumonic or neoplastic) and transudative pleural effu-
sions. In patients with an infectious pleural effusion, a high
level of sTREM-1 is more suggestive of a parapneumonic
rather than a tuberculous effusion.
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